reactiv
inflammatori
arthriti
known
mani
year
follow
genit
infect
intracellular
bacteri
pathogen
chlamydia
trachomati
individu
recent
studi
sever
group
demonstr
relat
bacterium
respiratori
pathogen
chlamydia
pneumonia
elicit
similar
arthriti
studi
organ
set
gastrointestin
pathogen
also
associ
engend
inflammatori
arthriti
rel
extens
howev
report
focus
coinfect
andor
organ
effect
coinfect
host
immun
system
rare
articl
review
extant
data
regard
infect
multipl
pathogen
joint
relat
engend
arthriti
suggest
number
research
area
must
given
high
prioriti
understand
therefor
treat
effect
manner
arthritid
genit
infect
bacteri
pathogen
chlamydia
trachomati
ctr
known
mani
year
function
trigger
reiter
syndrom
rs
reactiv
arthriti
rea
recent
studi
indic
chlamydi
aetiolog
even
patient
spondyloarthr
spa
epidemiolog
data
suggest
chlamydiainduc
reactiv
arthriti
crea
common
condit
previous
thought
clinician
often
fail
recogn
importantli
recent
control
studi
demonstr
crea
success
treat
combin
antibiot
therapi
therebi
rais
possibl
cure
possibl
highlight
increas
signific
awar
diagnosi
arthriti
spa
elicit
chlamydia
becom
clear
last
two
decad
two
chlamydi
speci
respons
caus
arthriti
ctr
relat
respiratori
pathogen
chlamydia
chlamydophila
pneumonia
cpn
elicit
diseas
via
persist
presenc
joint
cpn
essenti
ubiquit
popul
far
examin
rais
possibl
coinfect
involv
two
chlamydi
speci
might
signific
aetiolog
rea
andor
uspa
possibl
reinforc
observ
dna
wide
varieti
bacteri
speci
found
joint
patient
arthriti
polymicrobi
coinfect
wellknown
demonstr
clinic
import
infecti
diseas
oral
caviti
otiti
media
diabet
foot
wound
infect
chronic
infect
cystic
fibrosi
lung
clinic
entiti
gener
coinfect
concurr
bacteri
pneumonia
staphylococcu
aureu
complic
flu
infect
close
sequenti
respiratori
virus
plu
commens
bacteria
otiti
media
caus
bacteri
streptococcu
pneumonia
haemophilu
influenza
follow
coronaviru
respiratori
syncyti
viru
adenovir
infect
importantli
addit
acut
coinfect
chronic
infect
involv
human
immunodefici
viru
hiv
lead
concurr
bacteri
infect
mycobacterium
tuberculosi
pathogen
coinfect
involv
chlamydia
trachomati
ctr
neisseria
gonorrhoea
describ
often
screen
program
clinic
set
patient
gonorrhoea
also
report
concurr
chlamydi
infect
less
high
individu
thu
demonstr
wide
variat
depend
popul
examin
coinfect
relev
urogenit
context
includ
genit
mycoplasma
genit
ureaplasma
coinfect
mycoplasma
genitalium
ureaplasma
urealyticum
biovar
men
gonococc
urethr
associ
postgonococc
urethr
independ
ctr
addit
studi
healthi
individu
women
crosssect
sexual
transmiss
infect
sti
screen
program
nongonococc
urethr
chronic
prostat
report
coinfect
ctr
genitalium
homini
u
urealyticum
u
parvum
urogenit
specimen
implic
sexuallytransmit
urogenit
diseas
although
evid
pathogen
role
ureaplasma
speci
question
given
commens
state
urogenit
flora
mention
compel
evid
accumul
recent
year
support
caus
role
ctr
cpn
rea
spondyloarthr
spa
articl
review
evid
coinfect
involv
chlamydi
speci
report
patient
arthriti
spa
discuss
potenti
aethiopathogen
clinic
implic
infect
address
need
futur
basic
research
clinic
studi
improv
diagnosi
clinic
descript
treatment
coinfect
involv
ctr
cpn
first
describ
synovi
tissu
st
patient
reactiv
arthriti
rea
reiter
syndrom
rs
rheumatoid
arthriti
ra
later
also
patient
chronic
rea
undifferenti
spondyloarthr
uspa
recent
first
time
multipl
intraarticular
coinfect
chlamydia
mycoplasma
ureaplasma
report
patient
postvener
rea
mention
last
two
decad
establish
ctr
cpn
also
caus
spa
least
patient
due
abil
persist
joint
epidemiolog
preval
infect
cpn
significantli
higher
ctr
overal
observ
provid
reason
schumach
colleagu
assess
incid
cpn
dna
compar
ctr
st
sever
synovi
fluid
sf
sampl
patient
rea
arthritid
normal
joint
sampl
n
posit
cpn
compar
ctr
importantli
posit
organ
patient
diagnos
rea
diagnos
ra
pcrposit
cpn
dna
clear
differenti
clinic
featur
identifi
patient
posit
chlamydi
speci
reason
possibl
decid
two
caus
agent
diseas
case
interestingli
genit
infect
ctr
respons
elicit
half
case
rea
pulmonari
infect
cpn
respons
less
case
basi
discrep
unknown
must
relat
detail
genet
compon
howev
elicit
signific
level
synovi
inflamm
either
ctr
cpn
appear
accomplish
congruent
mean
transcript
highli
proinflammatori
chlamydi
protein
upregul
persist
synovi
infect
chlamydi
speci
undifferenti
spa
suggest
form
frust
rea
base
indirect
serolog
evid
preced
genitourinari
enter
infect
carter
colleagu
investig
preval
ctr
andor
cpn
dna
pcr
st
peripher
blood
monocyt
pbmc
patient
chronic
uspa
n
use
patient
osteoarthr
oa
n
control
thirtyeight
percent
patient
uspa
posit
st
ctr
cpn
togeth
oa
patient
posit
respect
patient
uspa
histori
possibl
ctr
infect
none
histori
cpn
infect
pbmc
posit
chlamydi
dna
patient
uspa
ctr
cpn
posit
st
ctr
cpn
togeth
data
suggest
chlamydi
infect
often
occult
organ
aetiolog
mani
patient
uspa
interestingli
patient
oa
degen
diseas
without
presum
infect
aetiolog
found
also
posit
chlamydi
dna
howev
less
frequent
rea
observ
clearli
suggest
level
subclin
essenti
invis
background
infect
present
popul
examin
question
role
chlamydia
innoc
bystand
caus
agent
joint
diseas
investig
doubleblind
placebocontrol
sixmonth
trial
combin
antibiot
doxycyclin
mg
twice
daili
rifampin
mg
daili
azithromycin
mg
daili
day
twice
weekli
rifampin
mg
daili
patient
chronic
crea
pcrposit
ctr
cpn
dna
pbmc
andor
st
sixtythre
percent
patient
undergo
activ
treatment
respond
compar
placebo
six
patient
undergo
antibiot
treatment
experienc
complet
remiss
compar
none
placebo
arm
interestingli
patient
went
remiss
azithromycin
rifampin
treatment
arm
suggest
combin
effect
studi
coinfect
ctr
plu
cpn
seen
pbmc
st
patient
includ
trial
patient
posit
coinfect
pbmc
undergo
combin
antibiot
treatment
neg
six
month
contrast
patient
placebo
remain
posit
six
month
recent
case
report
underlin
efficaci
chlamydi
coinfect
rea
patient
convincingli
demonstr
coinfectionposit
cultur
ctr
cpn
sf
cultur
posit
bronchoalveolar
lavag
bal
cpn
real
time
polymeras
chain
reaction
rtpcr
posit
chlamydia
spp
sf
rtpcr
posit
bal
cpn
achiev
complet
remiss
antibiot
combin
azithromycin
plu
rifampicin
three
month
anoth
two
month
discontinu
medic
one
month
induc
persist
organ
return
activ
development
cycl
result
control
trial
case
report
promis
support
caus
role
chlamydia
arthriti
result
also
engend
sever
question
control
trial
onethird
patient
nonrespond
rate
complet
remiss
rather
low
efficaci
combin
antibiot
treatment
need
optim
dose
durat
therapi
possibl
control
trial
coinfect
involv
bacteria
associ
rea
identifi
may
prevent
respons
treatment
regimen
latter
obviou
possibl
given
recent
report
multipl
coinfect
chlamydi
spp
mycoplasma
ureaplasma
patient
postvener
rea
case
studi
postvener
rea
n
assess
presenc
ctr
cpn
mhomini
u
urealyticum
sampl
st
sf
pbmc
time
synovectomi
fourmonth
antibiot
combin
therapi
combin
ciprofloxacin
tetracyclin
roxithromycin
coinfect
two
three
differ
bacteria
detect
patient
frequent
st
n
ctr
plu
cpn
n
ctr
plu
homini
n
ctr
plu
cpn
plu
homini
pbmc
n
c
tr
plu
u
urealyticum
n
ctr
plu
cpn
n
c
tr
plu
homini
n
ctr
plu
cpn
plu
homini
n
ctr
plu
cpn
plu
u
urealyticum
sampl
synovectomi
combin
antibiot
combin
ctr
found
pbmc
sampl
patient
diagnosi
patient
posit
cpn
homini
therapi
still
posit
cpn
one
patient
remain
posit
homini
therapi
patient
posit
u
urealyticum
becam
neg
therapi
synovectomi
probabl
contribut
notabl
remiss
patient
hypertroph
st
contain
infecti
agent
remov
intraarticular
coinfect
ctr
n
gonorrhoea
report
date
best
knowledg
although
urogenit
coinfect
frequent
describ
howev
coinfect
chlamydia
arthritogen
bacteria
relev
borrelia
burgdorferi
one
import
arthritistrigg
organ
western
countri
therefor
import
differenti
diagnosi
chlamydi
arthriti
simultan
detect
dna
ctr
b
burgdorferi
sf
patient
unexplain
oligoarthr
first
describ
putschki
colleagu
coincident
histori
tick
bite
ctr
posit
urogenit
smear
patient
posit
serolog
bacteria
patient
posit
b
burgdorferi
serolog
combin
ctr
posit
urogenit
smear
patient
support
extent
suggest
bacteria
may
caus
joint
inflamm
individu
case
less
convinc
implic
role
coinfect
involv
yersinia
enterocolitica
cpn
mycoplasma
pneumonia
borrelia
arthriti
base
mere
serolog
lymphocyt
transform
test
thu
evid
coinfect
chlamydia
spp
one
anoth
mycoplasma
andor
ureaplasma
speci
joint
base
molecular
genet
test
avail
rea
uspa
undifferenti
oligoarthr
case
report
case
seri
studi
pathogen
clinic
implic
discuss
gener
analog
evid
establish
bacteri
coinfect
relev
vitro
studi
tradit
reductionist
approach
defin
detail
pathogenesi
studi
singl
bacteri
infect
isol
longer
adequ
understand
process
polymicrobialcoinfect
context
especi
true
anatom
context
normal
includ
complex
microbi
commun
gastrointestin
tract
oral
caviti
reductionist
approach
also
inadequ
elucid
pathogen
mechan
diseas
context
involv
complex
biofilm
inde
presenc
nonpathogen
organ
opportunist
pathogen
low
level
anatom
site
one
pathogen
attenu
pathogenesi
function
pathogen
increas
damag
mani
case
simpli
possibl
present
defin
certainti
detail
contribut
organ
coinfect
context
overal
panel
pathogen
featur
cite
one
set
exampl
latter
earlier
report
group
st
andor
sf
sampl
patient
varieti
arthritid
studi
use
multiplex
pcr
system
capabl
identifi
organ
mani
genera
sampl
chosen
studi
known
pcrneg
ctr
cpn
b
burgdorferi
sever
mycoplasma
speci
sinc
one
purpos
studi
determin
whether
bacteria
known
elicit
joint
diseas
could
identifi
patient
rea
ra
oa
psoriat
arthriti
diseas
patient
dna
sampl
pcrposit
st
organ
identifi
via
dna
sequenc
analysi
gener
pcr
product
includ
genera
pseudomona
moraxella
acinetobact
salmonella
other
pcrposit
sampl
prove
multipli
infect
organ
genera
xanthomona
stenotrophomona
enterobact
other
identifi
addit
relev
index
organ
could
identifi
specif
aspect
synovi
pathogenesi
attribut
either
organ
multipli
infect
sampl
address
issu
relat
result
biofilm
format
infect
normal
complex
microbiolog
commun
human
limit
data
regard
coinfect
st
andor
sf
sampl
rea
spa
relev
patient
avail
current
explor
effect
coinfect
relev
organ
andor
host
immun
respons
vitro
system
vivo
anim
model
system
one
set
studi
publish
group
number
year
ago
first
intend
examin
effect
mycoplasma
contamin
cultur
ctr
cpn
goal
clear
cultur
contamin
organ
five
ctr
genit
trachoma
strain
cpn
isol
confirm
includ
mycoplasma
contamin
restrict
analys
plu
select
dna
sequenc
rrna
produc
pcr
identifi
homini
fermentan
hyorhini
isol
growth
ctr
cpn
cultur
substanti
inhibit
cultur
use
isol
contamin
variou
mycoplasma
speci
compar
growth
cultur
seed
nonmycoplasmacontain
strain
clear
effect
synovi
coinfect
chlamydia
mycoplasma
might
diseas
induct
durat
specul
put
forth
might
made
wors
host
immun
respons
chlamydia
attenu
situat
relat
studi
cpn
ctr
infect
human
monocyt
cultur
prostaglandin
pge
product
demonstr
induc
although
product
high
induc
treatment
monocyt
lipopolysaccharid
lp
e
coli
interestingli
product
pge
higher
cultur
monocyt
infect
ctr
compar
similar
cultur
infect
cpn
cultur
infect
strainsisol
either
chlamydi
speci
along
fermentan
pge
product
increas
synergist
manner
thu
coinfect
human
cell
cultur
either
chlamydi
speci
plu
mycoplasma
affect
growth
chlamydia
also
host
respons
infect
studi
anoth
group
investig
relationship
coinfect
ctr
ureaplasma
parvum
latter
common
commens
human
femal
genit
system
treatment
chlamydiainfect
cultur
hela
cell
type
result
intracellular
chlamydia
transit
persist
infect
state
coinfect
ctr
u
parvum
releas
ctr
infect
hela
cell
persist
howev
absenc
presenc
u
parvum
attenu
chlamydi
growth
host
hela
cell
inhibit
tryptophan
product
via
induct
enzym
indoleamin
ido
amino
acid
requir
intracellular
growth
matur
ctr
u
cultur
ctrinfect
hela
cell
presenc
former
organ
either
viabl
heatkil
form
effect
ido
gene
express
enzym
product
recent
review
describ
studi
respiratori
system
coinfect
streptococcu
pneumonia
common
human
pathogen
particular
interest
organ
issu
mucos
pathogen
ctr
cpn
synovi
pathogenesi
sequela
prior
mucos
infect
either
latter
organ
coinfect
pneumonia
haemophilu
influenza
common
popul
studi
particularli
children
vitro
cocultur
studi
former
repeatedli
demonstr
clear
growth
fit
advantag
latter
convers
true
coinfect
studi
murin
model
investig
mechan
vivo
effect
implic
complex
modul
host
immun
respons
result
select
virul
pneumonia
strain
convers
coinfect
pneumonia
aureu
former
strongli
attenu
carriag
latter
probabl
also
via
immunemedi
mechan
coinfect
pneumonia
influenza
viru
latter
attenu
immun
suppress
bacterium
engend
synerg
pathogenesi
two
thu
interact
multipl
pathogen
mucos
surfac
complex
process
outcom
term
pathogenesi
combinatori
result
individu
pathogen
mechan
issu
interest
observ
postgonococc
rea
suggest
chlamydi
aetiolog
due
urogenit
coinfect
ctr
neisseria
gonorrhoea
miss
confirm
intraarticular
coinfect
sever
possibl
explan
lack
target
search
joint
sampl
acut
phase
gonococc
arthriti
andor
postgonococc
arthriti
one
studi
search
chlamydia
ureaplasma
neisseria
dna
sf
patient
inflammatori
arthriti
n
includ
small
number
clinic
associ
vener
infect
n
gonococc
arthriti
n
rsrea
observ
coinfect
one
patient
gonococc
arthriti
diagnos
sfposit
pcr
neisseria
dna
proven
chlamydia
cervic
neg
coinfect
ctr
joint
n
gonorrhoea
may
induc
asept
rea
suscept
patient
treat
penicillin
earli
adequ
allow
gonococci
surviv
accessori
gland
oviduct
hypothesi
suggest
basi
similar
clinic
pattern
compar
rs
greater
lymphocyt
stimul
induc
gonococc
antigen
signific
patient
postgonorrho
asept
arthriti
healthi
control
antibiot
regim
gonococci
simultan
erad
coincid
chlamydi
infect
allow
chlamydia
invad
inflam
joint
dissemin
urogenit
reservoir
diagnosi
rea
commonli
base
histori
preced
infect
urogenit
test
ctr
serolog
antibodi
arthritogen
bacteria
rare
st
sf
sampl
avail
molecular
test
target
bacteri
dna
research
clinic
laboratori
commerci
test
kit
approv
routin
applic
rheumatolog
set
thu
press
need
address
diagnost
identif
coinfect
arthriti
first
research
initi
need
investig
patient
undifferenti
arthriti
rea
undifferenti
spa
intraarticular
coinfect
involv
chlamydia
urogenit
mycoplasma
ureaplasma
spp
aim
confirm
find
mention
postvener
rea
date
report
one
research
unit
expand
investig
entir
spectrum
arthritid
potenti
consequ
coinfect
also
interest
determin
whether
coinfect
may
found
eg
chlamydia
plu
enter
bacteria
pneumonia
fermentan
salivarium
arthritid
implic
caus
agent
arthriti
whose
dna
found
pcr
sf
diver
joint
diseas
note
recent
studi
report
coinfect
pneumonia
homini
arthritid
sf
sampl
patient
ra
use
multiplex
pcr
method
develop
rapid
simultan
identif
speci
develop
sensit
specif
multiplex
molecular
test
method
necessari
address
topic
rais
sinc
contrast
septic
arthriti
number
noncultur
bacteria
found
joint
patient
chlamydi
rea
usual
quit
low
experi
dna
extract
method
pcr
protocol
must
adapt
sf
st
milieu
reach
adequ
level
perform
assum
research
laboratori
develop
test
protocol
design
use
joint
sampl
identif
mycoplasma
ureaplasma
enter
approach
appli
simultan
detect
mycoplasma
spp
sf
sampl
patient
ra
multiplex
pcr
translat
research
protocol
data
clinic
practis
requir
develop
commerci
avail
test
kit
adapt
sf
analys
anyplex
ii
kit
seegen
eurobio
market
simultan
detect
ctr
mycoplasma
spp
ureaplasma
spp
involv
sexual
transmit
infectionsha
identifi
coinfect
patient
screen
genit
infect
thu
give
promis
develop
multiplex
rtpcr
assay
use
rheumat
patient
realiz
adapt
joint
sampl
need
earlier
observ
demonstr
commerci
assay
develop
urogenit
sampl
allow
detect
ctr
clinic
specimen
lower
sensit
inhous
develop
pcr
concert
optimis
sampl
prepar
sf
chlamydia
dissemin
monocytesmacrophag
origin
site
infect
peripher
blood
settl
joint
shown
demonstr
chlamydi
dna
pbmc
prepar
patient
rea
undifferenti
spa
henc
import
addit
research
topic
centr
investig
peripher
blood
detect
coinfect
patient
arthriti
develop
commerci
multiplex
pcr
assay
peripher
blood
test
great
import
rapid
diagnosi
overcom
limit
avail
joint
sampl
everi
day
clinic
practis
comprehens
research
program
outlin
prerequisit
understand
clinic
implic
chlamydi
coinfect
arthriti
spa
develop
therapeut
strategi
direct
multipl
persistentlyinfect
organ
diseas
cours
rea
selflimit
remit
chronic
progress
factor
known
associ
progress
acut
rea
chronic
spa
presenc
posit
famili
histori
ankylos
spondyl
spa
presenc
chronic
lesion
gut
one
envis
sever
scenario
explain
coinfect
might
impact
crea
coinfect
may
induc
sever
inflamm
arthrit
joint
acut
phase
diseas
andor
may
prolong
selflimit
phase
diseas
andor
may
caus
relaps
diseas
andor
may
support
chronic
diseas
cours
one
sever
coinfect
bacteria
elimin
vitro
studi
shown
coinfect
fermentan
ctr
cpn
suppress
chlamydi
growth
turn
may
induc
persist
infect
result
addit
stimul
pge
product
human
monocyt
elicit
chlamydi
persist
either
speci
synovium
via
whatev
mean
virtual
guarante
signific
sustain
level
local
inflamm
given
detail
public
persist
infect
chlamydia
display
number
unusu
morpholog
molecular
genet
characterist
contribut
product
inflamm
host
morpholog
persist
ctr
cpn
highli
aberr
reflect
sever
attenu
product
immunodomin
shapedetermin
major
outer
membran
protein
organ
select
transcript
attenu
one
facet
major
adjust
overal
panel
chlamydi
gene
express
characteris
persist
mention
probabl
critic
adjust
relev
inflamm
strong
upregul
express
bacteri
heat
shock
proteinencod
hsp
gene
product
recogn
host
power
proinflammatori
molecular
genet
aspect
persist
also
contribut
various
induct
mainten
inflamm
effect
factor
may
caus
sever
prolong
even
chronic
diseas
describ
coinfect
ctr
u
parvum
vitro
hela
cell
system
treat
promot
matur
ctr
reticul
bodi
elementari
bodi
independ
ido
express
clearli
suggest
novel
surviv
strategi
ctr
exposur
cours
critic
host
defenc
factor
elimin
chlamydia
alreadi
mention
question
aris
doubleblind
placebocontrol
sixmonth
trial
combin
antibiot
doxycyclin
mg
twice
daili
rifampin
mg
daili
azithromycin
mg
daili
day
twice
weekli
rifampin
mg
daili
patient
chronic
crea
onethird
patient
nonrespond
rate
complet
remiss
rather
low
suppos
coinfect
involv
bacteria
associ
rea
identifi
case
effect
antibiot
candid
bacteria
must
question
exampl
doxycyclin
effect
low
erad
rate
genitalium
erad
rate
azithromycin
decreas
significantli
due
rapid
emerg
resist
day
azithromycin
treatment
mg
day
mg
follow
daysi
need
effect
erad
urogenit
coinfect
ctr
genitalium
may
explain
combin
azithromycin
rifampin
effect
induc
remiss
chronic
crea
although
chlamydi
infect
alon
effect
elimin
combin
azithromycin
rifampin
vitro
cell
summari
studi
necessari
identifi
effect
antimicrobi
combin
therapi
includ
coinfect
cure
chlamydi
arthriti
sever
recent
report
coinfect
cite
herein
involv
chlamydia
homini
u
urealyticum
patient
postvener
rea
indic
clear
critic
unmet
need
futur
research
understand
natur
consequ
coinfect
diagnost
clinic
cours
treatment
chlamydi
arthriti
spa
particular
holist
data
collectioninclud
larg
spectrum
potenti
urogenit
respiratori
even
enter
pathogen
candid
coinfectionswould
help
advanc
understand
role
bacteria
arthriti
spa
improv
knowledg
need
regard
risk
factor
coinfect
clinic
circumst
chlamydia
interact
pathogen
mechan
behind
pathogenpathogen
interact
includ
experiment
studi
